Biohaven
BHVN | NYSE
$13.80
-$0.02 (-0.14%)
At close: Nov 16, 2026, 4:00 PM ET
$13.90
+$0.10 (+0.72%)
After-hours:
Nov 16, 2026, 6:54 PM ET
Biohaven Company Profile
Company profile explainedCompany Profile
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Key Executives
| Name | Position |
|---|---|
| Vladimir Coric | Chairman & Chief Executive Officer |
| John McGill | Chief Technology Officer |
| Matthew Buten | Chief Financial Officer |
| Warren Volles | General Counsel & Chief Legal Officer |
| Bruce D. Car DACVP | Chief Innovation Officer |
| Clifford Bechtold | President, GM of Biohaven Ireland & Chief Compliance Officer |
| Deb Young | Senior Director of Regulatory Affairs & Operations |
| George C. Clark | Vice President & Chief Accounting Officer |
| Jennifer Porcelli | Vice President of Investor Relations |
| Kimberly Gentile | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 22, 2026 | 8-K | Current Report |
| Oct 15, 2026 | 8-K | Current Report |
| Sep 17, 2026 | 4 | Filing |
| Sep 10, 2026 | 8-K | Current Report |
| Aug 26, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 3 | Filing |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 10, 2026 | 8-K | Current Report |
Biohaven
| Country | United States |
| IPO Date | Sep 23, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 274 |
| CEO | Vladimir Coric |
Contact Details
215 Church Street New Haven,
Connecticut 06510 United States
Stock Details
| Ticker Symbol | BHVN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001935979 |
| CUSIP Number | G1110E107 |
| ISIN Number | VGG1110E1079 |
| SIC Code | 2834 |
Recent News
- 18 days ago / prnewswire.comBiohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
- 26 days ago / barrons.comBiohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
- 26 days ago / benzinga.comBiohaven Rebounds With FDA Review Date for Rare Disease Drug
- 1 month ago / benzinga.comBiohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
- 1 month ago / gurufocus.comBiohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
- 2 months ago / gurufocus.comBiohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
- 2 months ago / prnewswire.comBiohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
- 2 months ago / barrons.comBiohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
- 2 months ago / benzinga.comFDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
- 2 months ago / reuters.comUS FDA pauses new enrollment in Biohaven's epilepsy drug trials
Add to Watchlist
Select watchlists to add or remove BHVN